WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 42'6901 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 39'1371 Child (under 5 years) mortality rate: 52

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 63'489  63'136  62'783  62'427  62'066  58'951  57'214  56'303 
Births 770  770  771  772  771  695  777  692 
Surviving infants 767  767  768  768  768  692  771  683 
Pop. less than 5 years 3'902  3'969  4'028  4'017  3'899  3'543  3'826  3'409 
Pop. less than 15 years 11'157  11'107  11'078  11'021  10'899  11'198  10'885  11'829 
Female 15-49 years 14'507  14'566  14'610  14'649  14'691  14'189  14'154  13'171 

Number of reported case

(Click for retrospective incidence data for United Kingdom of Great Britain and Northern Ireland (the))
Diphtheria
Japanese encephalitis
Measles 133  1'919  2'092  1'112  443  104  28'228  147'962 
Mumps 2'958  4'718  3'178  2'716  4'527  1'089 
Pertussis 4'046  6'090  11'980  1'243  518  866  16'605  22'924 
Polio*
Rubella 13  70  31  75 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 18  30 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          95  95  95  95  94  91  85 
DTP4          90 
HepB_BD         
IPV1         
HepB3         
Hib3          95  95  95  95  94  91 
JapEnc         
MCV1          93  93  92  90  89  88  89 
MCV2          89  88  87  85  84  76 
PCV1         
PCV3          93  93  92  90  89 
Pol3          95  95  95  95  94  91  90 
Rota1         
Rota_last         
Rubella1          93  95  92  90  93 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
DTP1 98  98  98  98  98  97  94  66 
DTP3 95  95  95  95  94  91  84  41 
HepB3
HepB_BD
Hib3 95  95  95  95  94  91 
MCV1 93  93  92  90  89  88  87  53 
MCV2 89  88  87  85  84  76 
PCV3 93  93  92  90  89 
Pol3 95  95  95  95  94  91  92  81 
Rota_last

Number of districts in the country 174  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 92
From 80 to 89% 7
From 50 to 79% 1
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes At birth to high risk groups only, but some areas with high proportion of risk groups offer it universally at birth
DTaPHibIPV 2, 3, 4 months; Yes
DTaPIPV 3-5 years; Yes and pregnant women
HPV 12-13 years (x2); Yes
HepB birth; 1, 2, 6 months; Yes High risk groups only
HibMenC 12-13 months; Yes
Influenza 2-3 years; >=65 years; Yes and risk groups
MMR 12-13 months; 3-5 years; Yes Additional screening offered to susceptible women identified through antenatal services.
MenACWY Issued for use in specific groups (e.g. asplenics)
MenC_conj 3 months; 14-18 years; Yes
Pneumo_conj 2, 4, 13 months; Yes
Pneumo_ps >=65 years; Yes At risk groups from 2 years
Rabies st contact; +7, +28 days; Yes
Rotavirus 2, 3 months;
TdIPV 13-18 years; Yes
Varicella 1st contact; Non-immune HCW

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number   151  152  151  151  152  173 

System performance

Total Nº districts in country number 174  176  176  421  177  173  173 
Nº districts with DTP3 coverage >=80% number 172  175  176  176  177  166  159 
% of districts with DTP3 coverage >=80% From 0 to 100% 99  99  100  42  100  96  92 
Nº districts with measles (MCV1) coverage >=95% number 89  67  33 
% of districts with MCV1 coverage >=95% From 0 to 100% 51  38  19 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes           
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes        Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.